NCT03283007View on ClinicalTrials.gov

Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2

PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Lung-transplant Recipients
Interventions
DRUG

Nintedanib

Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months

DRUG

Placebo

Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months

Trial Locations (1)

92150

Foch Hospital, Suresnes

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03283007 - Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2 | Biotech Hunter | Biotech Hunter